Card is happy to announce that on February 19th, that we will be teaming up with Lineagen to offer an open house presentation and discussion on the benefits of genetic testing with individuals on the spectrum.
CARD and Lineagen have established a clinical partnership so that CARD clients can have easier access to chromosomal microarray analysis (CMA).
CMA can identify genetic conditions that underlie the diagnosis of ASD. Having the CMA genetic diagnosis can personalize medical management for your child and inform reccurence risk for additional family members. Lineagen’s CMA, called First Step, can identify more genetic variants related to ASD than any other CMA. The Lineagen test also comes with genetic counseling services and a personalized eReport.
Lineagen is great because most private insurers cover CMA and Lineagen works hard with families to determine any out-of-pocket costs a family may incur prior to testing.
RSVP for the open house at firstname.lastname@example.org